We have developed and optimized a procedure for the quantitation of non-enzymatically glycated apolipoprotein B (apo B). Glycated and non-glycated apo B were separated from serum using m-aminophenylboronate affinity chromatography, determined by immunophelometry and the percentage of glycated apo B was calculated. The measuring range of the assay was 2,9-185 mg/dL apo B.
The within-and between-run coefficients of variation were < 7 . 4070 and 14· 6070, respectively, and recovery was> 98070. Free glucose in serum did not affect the results at concentrations below 25 mmol/L. In 45 non-diabetic subjects the mean concentration of glycated apo B was 4.3070 (SD 1070). In type 1 (n = 17) and Type 2 (n = 60) diabetic patients the mean glycated apo B concentrations were 5· 3070 (SD 0'7070) and 5 ·9070 (SD 1·1070), respectively, significantly higher than in controls (P<O·OOI).
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Apolipoprotein B (apo B) is the major protein of the low-density lipoproteins (LDL). Nonenzymatic glycation (the formation of a stable ketoamine adduct between glucose and free aminogroups of protein) is one of the postsecretory modifications of LDL that affects its atherogenic potential and has been implicated in the premature and severe atherosclerosis associated with diabetes mellitus.I'<' A number of mechanisms may be involved. First, recognition of glycated LDL by the classic LDL receptor is impaired since glycation of apo B may inhibit the physiological ability of LDL to be metabolized by the LDL receptor pathway.v" A second alteration is enhanced uptake of LDL by monocyte-derived macrophages stimulating the formation of foam cells, an early feature of atherosclerosis.I-" Third, platelet aggregation is increased in the presence of glycated LDL. 9 Fourth, glycated LDL particles may have increased susceptibility to subsequent oxidative damage. 10
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Finally, LDL modification can be sufficiently extensive to provoke an antibody response, and the formation of potentially atherogenic LDL-immune complexes. 11 The true clinical significance of these findings is, however, unclear because the extent of in vivo glycation occurring in typical diabetic patients has not been investigated in detail and preliminary findings are conflicting.P"" We developed a method for the measurement of glycated apo B in human serum utilising a combination of boronate affinity chromatography and immunonephelometry, and employing commercially available reagents. Using this assay, we determined the serum concentration of glycated apo B in diabetic and non-diabetic populations to investigate if, and to what extent, glycated apo B is increased in diabetes mellitus.
MATERIALS AND METHODS

Procedure
Two hundred microlitres of serum were applied to the top of an O' 5 mL m-aminophenylboronate affinity chromatography minicolumn (Glycotest II, Pierce Chemical Co., Rockford, IL, USA). The columns were equilibrated with 10 mL of ammonium acetate-based equilibration/ wash buffer (250 mmol/L ammonium acetate, 50 mmol/L magnesium chloride and 5 mL/L phenoxyethanol, pH 8,05) before elution of non-glycated proteins from the columns using a further 3 mL of equilibration/wash buffer. Glycated apo B was then eluted from the columns using 3 mL sorbitol elution buffer (200 mmol/L sorbitol, 500 mmollL sodium chloride, 3 mmollL sodium azide, 25 mmollL Hepes, pH 10,25). Concentrations of apo B in the glycated ('elution buffer') and non-glycated ('wash buffer') fractions of sera recovered from the affinity columns were determined in duplicate by an automated immunonephelometric assay on a Behring nephelometer 100 with polyclonal apo B-specific rabbit antibody (Behringwerke AG, Marburg, Germany). The low levels of apo B present in the glycated and non-glycated fractions necessitated performing the assay without sample pre-dilution. We calibrated the assay at least once per week with standards provided by Behring and before each analytical run the apo B concentration of a control serum specimen (Behringwerke AG) was checked. The percentage glycated apo B was calculated using the following formula: 070 glycated apo B = 100 x bound/ (bound + unbound) x 16, where the factor 16 represents the dilution of serum by column eluent.
Controls used for the evaluation and performance of the assay and for the precision experiments were prepared by in vitro glycation of human sera. A human serum pool was incubated in 100 mmol/L D-glucose and 1· 5 mmollL sodium azide at 37°C for 2, 8 and 15 h to produce the three control materials used in each experiment. The reaction was terminated by extensive dialysis for at least 3 h at room temperature against a buffer containing 150 mmollL sodium chloride and IOmmollL sodium phosphate, pH 7·4. The buffer was changed every 30 min. The control materials were stored at -20°C for periods not exceeding 6 months.
Subjects
The diabetic patients (n = 77) recruited for our study were out-patients at the Brescia Diabetes Centre. Of the diabetic group, 17 (13 men, 4 women; age range 22-58 years) were insulindependent (type 1) and 60 patients (37 men, 23 women; age range 39-67 years) were non-insulin-dependent (type 2). Venous blood samples were collected without anti-coagulant after an overnight fast. After the blood had clotted, the tube was centrifuged at 1400 x g for 30 min and the serum was separated and stored at 4°C until analysis (within 4 h of sample collection). Glycaemic control was assessed by routine monitoring of glucose, glycated haemoglobin and fructosamine concentrations. The mean values were 10· 3 mmollL (SD 3·1 mmollL) for fasting glucose, 6· 9% (SD 1. 4%) for glycated haemoglobin and 346 JLmol/L (SD 57 JLmollL) for fructosamine. Our reference intervals for these analytes are 4· 2-6' 1 mmollL for glucose, 3-6% for glycated haemoglobin and 205-285 JLffiollL for fructosamines. The non-diabetic control subjects (17 men, 28 women) were apparently healthy hospital staff members (ages 22 to 51 years).
RESULTS
Assay optimization
Before studying the quantitative aspects of the method, we tested the possible effect of the elution buffer, containing sorbitol, in the immunonephelometric assay of apo B. A human serum pool (mean apo B concentration: 123 mg/dL) was diluted with increasing quantities of the elution buffer. The recovery of total apo B at the concentrations corresponding to those of chromatographic fractions was 97 .6% (SEM 5%; n = 4), showing the absence of sorbitol interference.
To determine whether glycation of apo B altered the interaction between the apo B antibody and its antigen in final quantitation by the immunonephelometric assay, serum samples were incubated over approx 72 h with 100 mmol/L glucose solution. Despite an average [mal glycated fraction of 25%, total apo B recovery measured immunologically was 107·3 % (SEM 6%; n = 4).
This recovery data demonstrated that the antibody used to estimate apo B recognizes the glycated form to the same extent as the nonglycated form (P= 0·40 comparing recoveries of non-glycated and extensively glycated apo B). We also tested whether the glucose concentration in the serum sample interfered with the affinity chromatography. The effect of free glucose in the sample appeared negligible below 25 mmollL. At higher concentrations a significant decrease in measured percentage glycated apo B was observed. Clearly glucose interferes with the binding of glycated apo B on the column matrix, but only at very high concentrations. Serum samples did not, therefore, require pre-treatment before chromatography, if the glucose concentration in serum was below 25 mmollL. We always checked the glucose concentration in the diabetic samples prior to glycated apo B estimation to ensure the level was less than 25 mmollL. Figure 1 shows the elution profile generated with the affinity columns using standard volumes of the equilibration and elution buffers, i.e. 6 mL. As can be seen, apo B was detectable only in the first 3 mL of each eluate. Thus, to obtain higher concentrations of apo B in both non-glycated and glycated pooled fractions for a better response in the immunonephelometric assay, we used 3 mL of each buffer in the final procedure rather than the 6 mL generally used.
To regenerate the columns for another assay, we added 5 mL of 500 mmollL sodium chloride in Tris/HCl buffer, 100 mmollL, pH 8· 5, to each column. When about 3 mL had passed through the column, the caps were replaced and the columns stored at 4 DC. To confirm that the columns could be reused, we used both nondiabetic and diabetic specimens (n = 6) to compare fresh with regenerated columns. Average values of 5·651170 (SD 1'8%) versus 5·27% (SD 1'4%) glycated apo B were obtained for fresh and regenerated columns, respectively. There was no significant difference between these values (P=0·28).
We determined the effect of temperature by performing the affinity assay at 1DC intervals between 19 and 25 DC using a serum specimen, assayed five times at each temperature. Columns and buffers were maintained at ±0·2 DC at each step with use of a water jacket around columns. We found that the results decreased by an average 0'3% glycated apoB per I DC temperature increase. Thus, an increase in the ambient temperature from 20 to 25 DC results in a decrease in % glycated apo B results of approximately 1· 5% absolute (mean glycated apo B value, 5%). To obtain optimal run-to-run consistency of the glycated apo B results, we performed all assay runs at the same temperature (21DC ± 1DC).
Linearity and detection limit
The measuring range of the apo B assay was 0·18 to 11·6 mg/dL. After correction for the sample dilution, the analytical sensitivity of the immunonephelometric assay was thus approximately 2· 9 mg/dL. The studies on non-diabetic and diabetic subjects (see below) demonstated that this range was adequate to cover the levels of glycated apo B seen in these two populations. Precision Within-run preCISIOn was determined by 10 replicate determinations of three control sera with normal (4%), above-normal (5' 5%) and high (8%) glycated apo B concentrations, prepared by in vitro glycation of human serum. Between-run precision was determined from data on the same serum samples obtained in eight different analytical batches. Within-run coefficient of variation (CV) was between 5·7% and 7·4%. At the normal glycated apo B concentration, the CV for between-run precision was 14'6%, whereas for sera with abnormal concentrations, betweenrun CV improved to < 10%. In addition, the analytical imprecision was monitored weekly with internal quality control material consisting of pooled human serum. The monthly SD for glycated apo B assay over 4 months ranged from O'33 to 0·54% at a mean concentration near 4'5%; the median SD was 0'51 %, giving a CV of 11·3%.
Recovery
Recovery of the affinity column procedure for apo B was assessed by measuring the apo B concentrations of the two eluted fractions and comparing their sum with the apo B concentration in the original serum sample applied to the column. The recovery of apo B was 98· 3% (SEM 3%; n=19).
In vitro glycation experiments
Incubation of serum at high glucose concentrations resulted in a substantial increase of apo B Serum glycated apo B in patients and controls Figure 2 shows the distribution of glycated apo B, expressed as percentage of total, in the non-diabetic control group. As can be seen, the distribution of values was gaussian (coefficient of skewness, -O' 23 ± 0'37; coefficient of kurtosis, -0'45 ±0'73) with a mean concentration of 4·3070 (SD 1'0070) . Glycation of apo B was significantly higher in diabetic patients than in control subjects (Fig. 3) , the mean value being 5·3070 (SDO'70J0) for the type I group and 5' 9070 (SD 1, 1070) for the type 2 group, respectively. The percentages of glycated apo B were not significantly different between the two diabetic groups, although total apo B was higher in type 2 (135 mg/dL, SD 27 mg/dL) than in type 1 patients [99 mg/dL, SD 24 mg/dL (P<O·OOI)]. Finally, no significant correlations were found in diabetic patients between glycated apo B and traditional indices of glycaemic control, such as glycated haemoglobin (r= 0'119) or fructosamine (r=0·078). detection procedure. The ability of boronic acid affinity columns to separate glycated proteins from non-glycated proteins is well established and is the basis for their use in assays of glycated haemoglobin, albumin and total proteins for evaluation of diabetic status. I? Immunonephelometry provides a simple, rapid and precise way of measuring apo B in the eluates. Other approaches to the measurement of glycated apo B have been proposed in the past. Lyons et al. 12 and Jack 13 used ultracentrifugation for LDL isolation followed by separation of glycated LDL with affinity chromatography and determination of reduced glycosylamine adducts'? or of cholesterol content of glycated LDL. 13 Curtiss and Witztum'" used a radioimmunoassay with antibodies recognising glucitollysine adducts (non-specific for glycated apo B) after lipoprotein Apo B is the protein determinant for cellular recognition and uptake of LDL by the LDL receptor . 16 Glycation of lysine residues in apo B may compromise receptor-mediated internalization and catabolism of LDL, thereby interfering with cholesterol homeostasis and contributing to the pathogenesis of atherosclerosis."? A possible model involves glycated LDL, poorly recognized by the classic LDL receptor, accumulating to high extracellular concentrations and being cleared via alternative LDL receptors (such as the monocyte/macrophage scavenger receptor). These alternative LDL receptors stimulate accelerated rates of cholesterol ester synthesis and may therefore lead to the transformation of macrophages into the lipidladen foam cells characteristic of early atheromatous fatty streaks. Consequently, direct assessment of apo B glycation may have diagnostic and pathogenetic importance, particularly in diabetic subjects in whom increased glycation of plasma proteins is known to occur. In our method, the percentage of glycated apo B is quantified by a combination of affinity chromatography and a sensitive immunonephelometric
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Panteghini, Bonora and Pagani isolation by sequential ultracentrifugation. Press and Wilding l9 applied the fructosamine assay to fractions of purified LDL. Additionally, agarose gel electrophoresis separation followed by colorimetric detection of glycated lipoproteins by the fructosamine reaction has been proposed." Generally, these procedures were complex and cumbersome. More recently, maminophenylboronate affinity chromatography coupled with either imrnunoturbidimetry'" or immunoradiometric detection of the glycated apo W 5 have been proposed. However, very different results in sera of diabetic and nondiabetic people have been reported.tv" Our results were similar to those reported by Tames et a/. 15 who found non-enzymic glycation of apo B significantly greater in diabetic patients than non-diabetic control subjects. However, these authors used an immunoradiometric procedure for apo B quantitation, which is timeconsuming and not commercially available. According to previous reports,14,15,19 glycation does not have a significant effect upon the availability of antigenic sites on apo B. The inability of polyclonal antibody to distinguish glycated from non-glycated apo B probably reflects the inability of apoprotein side-chain chemical modification to alter the interaction between antibody and antigen. In contrast, a recent report 21 indicates that it is possible for apo B to be glycated to such an extent that specific monoclonal antibodies can be produced, allowing direct immunological detection of glycated apo B in serum.
Our data indicate that the fraction of glycated apo B in diabetic subjects is approximately I . 3-fold greater than that of control subjects. Few reports on glycated apo B levels in diabetics have been published until now. Lyons et a/. 12 15 found an increased level of glycated apo B in diabetic patients, clearly similar to our observations. The slight discrepancy of our percentage findings in diabetics with those reported by Tames et a/. 15 (7' 9070 ±O·4%) may be ascribed to the different populations studied, because data in non-diabetic controls were superimposed. Finally, our percentage glycated apo B levels agree with those in a preliminary report by Shea and Cohen using a competitive ELISA with specific monoclonal antibodies.P
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We found no significant correlations between glycated apo B values and the traditional indices of glycaemic control, such as glycated haemoglobin and fructosamine. This may be partly because LDL has a shorter circulating half-life (approximately 3 days) than the majority of plasma proteins.P While glycated haemoglobin and fructosamine assays reflect glycaemic control over a longer period of time, the levels of glycated apo B in plasma would be expected to reflect only very recent glycaemic control.
In conclusion, we have described a novel method for quantitation of glycated apo B. The procedure is simple and uses commercially available reagents. Using this method, we have demonstrated the presence of increased glycation of apo B in a relatively large group of diabetic patients. This finding may help to explain why diabetes, irrespective of type, is an independent risk factor in the development of atherosclerosis. However, further clinical studies should shed more light on the definitive atherogenic role of glycated apo B.
